Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR2 | Q8NFJ6 | 5/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.34 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565687 | 0.90 | PROKR2 (0.61) | PROKR2PKMBCHEMAP3K7TAB1 | |
| SCHEMBL565543 | 0.89 | PROKR2 (0.47) | PROKR2PKM | |
| SCHEMBL565544 | 0.89 | PROKR2 (0.62) | PROKR2PKMMAP3K7TAB1TACR1 | |
| SCHEMBL565385 | 0.88 | PROKR2 (0.47) | PROKR2 | |
| SCHEMBL565039 | 0.85 | PROKR2 (0.46) | PROKR2 | |
| SCHEMBL565013 | 0.83 | PROKR2 (0.44) | PROKR2OPRM1OPRK1 | |
| SCHEMBL565355 | 0.82 | PROKR2 (0.42) | PROKR2 | |
| SCHEMBL10107389 | 0.81 | PROKR2 (0.64) | PROKR2PKMOPRM1OPRK1TACR1 | |
| SCHEMBL564477 | 0.81 | PROKR2 (0.64) | PROKR2PKMOPRM1OPRK1TACR1 | |
| SCHEMBL565460 | 0.80 | PROKR2 (0.44) | PROKR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722896-B2 | Prokineticin receptor antagonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | PROKR2, PROKR1, GIPR | PROKR2 1/4885PKM 722/4885BCHE 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.